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Abstract 
Background: The outcomes of intragastric balloon (IGB) placement to achieve weight loss in 
obese patients with chronic kidney disease (CKD) have not been reported to date. This study aimed 
to assess the safety and efficacy of the IGB as a weight-loss treatment among this patient popula- 
tion. Methods: A prospective, single-arm, ‘first in CKD’ inter- ventional study was conducted in 
patients with a body mass index >35 kg/m2 and CKD stages 3–4, referred for weight loss. After 
clinical assessment, the IGB was endoscopically inserted into the stomach and kept in place for 6 
months. Complications, adverse events, acceptability, weight loss and metabolic responses were 
monitored over 6 months. Results: Eleven participants were recruited over 18 months. Two 
patients withdrew (1 prior to IGB insertion and 1 early removal after 3 days due to persistent 
vomiting) from the study; 9 patients completed the study. There were 5 epi- sodes of acute kidney 
injury (AKI), occurring in 3 patients. After 6 months, the mean body mass decreased by 9.6% (SD 
±6.8). Median waist circumference and total cholesterol de- creased significantly (–7.7 cm; 
interquartile range (IQR) –15.3 to –3.9; and –0.2 mmol/l; IQR –0.6 to –0.05, respectively), with no 
changes in estimated glomerular filtration rate, blood pressure, triglycerides, adipokines, 
inflammation, or arterial stiffness measured by carotid-femoral pulse wave velocity. At IGB removal, 
there was 1 new case each of gastritis and esophagitis. Conclusions: Treatment with IGB has only mod- 
erate efficacy on weight loss; yet it results in a high rate of complications in obese patients with 
established CKD. The risk of AKI may be raised due to increased risk of dehydration secondary to 
gastrointestinal symptoms associated with IGB placement and reduced baseline kidney function. 
 
 
Introduction 
Obesity is an independent contributory factor to the development and progression of chronic kidney disease 
(CKD) [1–3]. We have previously demonstrated the ef- ficacy and effectiveness of lifestyle interventions in obese 
patients with CKD [4, 5]. However, it may be desirable that greater weight loss be achieved in some patients, pos- 
sibly due to higher body mass index (BMI), comorbidities and/or personal preferences. Several studies have 
demonstrated that weight loss can be achieved successfully by performing bariatric surgery in obese patients 
with CKD [6–8]. However, there are challenges with all 3 common surgical procedures (gastric banding, Roux-
en-Y gastric bypass, and sleeve gastrec- tomy) in patients with CKD due to reports of band ero- sion, nutrient 
malabsorption, increased risk of hyperox- aluric nephrolithiasis, dehydration and acute kidney in- jury (AKI) [9–
11]. Large studies of registry data indicate that patients with CKD have an increased risk of adverse events 
following weight loss surgery, which advances as kidney function declines [12, 13]. Patients with stages 3–4 CKD, 
or moderate to advanced kidney impairment, are 1.5 times more likely to experience a complication after 
undergoing weight loss surgery than patients without CKD [12]. 
 
Intragastric balloon (IGB) treatment is safe and results in significant weight loss over the short term in patients 
with normal kidney function [14–16]. This may therefore be considered an alternative weight loss treatment 
meth- od for obese patients with CKD. The IGB is a fluid-filled silicone device that is inserted into the stomach 
endo- scopically and inflated to a fixed volume; this is done in order to restrict intake of food while still 
retaining the normal stomach function without malabsorption. Com- plications such as nausea are common 
and almost 1/3 of patients experience some gastric erosion [17]; however, rare but hazardous complications 
such as gastric perfora- tion and AKI have been reported [18, 19]. This study assessed the efficacy and safety 
of the IGB to facilitate weight loss in obese patients with CKD and to explore the effects of weight loss on 
metabolic syndrome and cardiovascular disease risk factors. 
 
Subjects and Methods 
Screening and Recruitment 
This was a single-arm, prospective ‘first in CKD’ intervention- al study in obese patients with CKD. It was 
designed to establish the efficacy of IGB insertion to achieve weight loss over 6 months, to monitor IGB-related 
complications and adverse events, and to examine patient acceptability of the procedure. The planned sample 
size of this initial safety and efficacy study was 12 patients. Obese patients (BMI >35 kg/m2), aged >18, with 
CKD stages 3–4 (4 variable Modification of Diet in Renal Disease (MDRD) study equation estimated glomerular 
filtration rate (eGFR) 15–59 ml/ min/1.73 m2), referred to dietetics services for weight loss, were eligible for 
inclusion in the study. The criteria for exclusion were as follows: patients who had undergone previous bariatric 
surgery or major abdominal surgery, patients who were pregnant or with acute malnutrition identified by 
Subjective Global Assessment (SGA) [20], or those who were unable to provide written informed consent. The 
study was conducted with the approval of the Na- tional Research Ethics Service North West Greater 
Manchester South Committee (12/NW/0811) and in accordance with the Hel- sinki Declaration of 1975, as 
revised in 2013 [21]. An independent study-monitoring committee oversaw the procedures followed in 
conducting this study. 
 
Once a 2–5% loss of body mass was achieved through a combi- nation of diet and exercise in our renal weight 
management clinic [5], patients were referred to the study gastroenterologist for as- sessment for IGB 
insertion. Prerequisite weight loss was required to enter the study to demonstrate changes to lifestyle factors, 
prior to insertion of the IGB. Prior to consenting to participate in the study, all patients were thoroughly 
informed about the possible benefits and known risks associated with IGB insertion. 
 
 
 
Intervention 
Patients underwent endoscopic insertion of the soft silicone IGB (Orbera, Allergan) through a procedure 
performed by an ex- perienced gastroenterologist. Once the IGB was in position, it was filled with 500–700 ml 
of saline and 10 ml methylene blue dye. Af- ter 6 months, the IGB was deflated and removed during endos- 
copy. At 1 and 2 weeks post IGB placement, serum creatinine was monitored to detect acute changes in kidney 
function, including episodes of AKI. AKI was defined on the basis of AKIN criteria of at least a 50% increase from 
baseline, or an acute rise of at least 26.4 μmol/l in 48 h, in serum creatinine [5]. 
 
All patients received from the study dietitian verbal and written communication for dietary education for weight 
loss with the IGB, prior to IGB insertion, and at 2–3 days post IGB insertion through telephone calls, and at 1, 6 
and 12 weeks during study visits. Infor- mation provided included sample meal plans, portion size guid- ance, 
reduction in snacking behaviour, and the importance of maintaining an adequate fluid intake. For the initial 
3 days post IGB insertion, only liquids were consumed, followed by a soft diet for 4 days. All patients were 
advised to drink 2 litres of fluids each day for the first week. From 1 week onwards, normal foods were eaten 
in very small portions, that is, quantity enough to fit a side plate (with a diameter of 200 mm), plus at least 
1.5 litres of non/ very low energy containing fluids (includes fat-free milk) con- sumed in 150–200 ml 
volumes, in between meals. Eating protein foods (lean meat, fish, pulses, eggs, and reduced fat dairy foods) at 
every meal was recommended, with the addition of vegetables at main meals, and a small portion of rice, 
pasta, bread, potatoes or other starchy vegetables, only if needed to reach satiety. 
 
 
All patients continued with appropriate medical treatment un- der the care of their nephrologist and general 
physician, including the use of angiotensin converting enzyme inhibitors, angiotensin receptor blockers and 
other blood pressure (BP)-lowering medica- tions, statins, erythropoietin, iron, vitamin D, phosphate binders, 
and treatment of diabetes and other pre-existing conditions. 
Outcomes and Measures 
The primary efficacy outcome was defined as at least a 10% re- duction in body mass 6 months after IGB 
insertion. Safety out- comes included complications associated with the IGB, adverse events and 
acceptability, measured by the early IGB removal rate. Early cessation of the study was planned if consistent 
inadequate weight loss or major early or late post IGB insertion complications occurred prior to the 
completion of the study. Events were re- viewed by an independent safety-monitoring committee through- 
out the study. Expected minor adverse events were nausea and vomiting, constipation, reflux and 
gastrointestinal discomfort. Major adverse events included, but were not limited to AKI, gas- trointestinal 
obstruction, spontaneous balloon deflation, epigas- tric pain and reflux. 
 
The secondary outcomes were changes in BP, blood lipids, waist circumference, insulin resistance measured 
by the homeo- stasis model of assessment of insulin resistance method (HOMA- IR) [22], proteinuria measured 
as the urinary protein to creatinine ratio, markers of inflammation, leptin, adiponectin and arterial stiffness, 
measured by carotid to femoral pulse wave velocity (PWV). Kidney function is reported as eGFR and is 
calculated us- ing the MDRD study equation; however, it was not selected as a study outcome due to the 
underestimation of kidney function by eGFR in obesity, and the error associated with measuring changes in 
kidney function as body size and body composition change [23– 26]. So kidney function must be interpreted 
bearing all these con- straints in mind. 
 
Baseline demographic data including date of birth, ethnicity, gender, medical history, current medications, 
and cause of CKD were recorded at the initial study visit. Using a wall-mounted stadiometer, the height was 
measured to the nearest 1 cm without the patients wearing shoes. Weight was measured to the nearest 0.1 kg 
on a calibrated electronic scale with the patient wearing light clothing and no shoes. Absolute weight loss was 
defined as the difference between baseline weight and weight at the time of measurement; it was calculated as 
an absolute value and as a percentage of baseline weight.  
 
Sitting BP was measured using an automated sphygmomanometer with an appropriate-sized upper arm cuff, 
3 times, and the average of the closest 2 readings was calculated. Waist circumferences were measured to the 
nearest 0.1 cm at the level of the umbilicus with a calibrated plastic tape measure. 
 
Laboratory Measures 
Morning venous blood samples were collected in standardized blood collection tubes (BD Vacutainer, New 
Jersey) after an over- night fast, for serum glucose, creatinine, leptin, adiponectin, inter- leukin-6 (IL-6), lipids, 
high-sensitivity C-reactive protein (hs- CRP), and insulin. Quantitative sandwich enzyme-linked immu- 
nosorbent assays were used to measure serum IL-6, leptin and adiponectin (R&D systems, USA), and insulin 
(Insulin Centaur, Siemens, UK). hs-CRP was measured using an immunoturbidi- metric assay (PZ Cormay, 
Poland). Standard enzymatic tech- niques were used to measure lipid fractions, total cholesterol, and glucose 
(Siemens Advia 2400, UK). The index of insulin resistance was calculated using the HOMA-IR equation [22], 
previously val- idated in patients with CKD [27]. Urine samples were analysed for total protein and creatinine using 
standard analytical methods and the protein-to-creatinine ratio was calculated. 
 
Arterial Stiffness 
Arterial stiffness was measured by carotid to femoral PWV by recording arterial pulse waveforms using the 
Vicorder oscillomet- ric device (Skidmore Medical, UK), validated against the recognised gold standard 
SphygmoCor system [28]. To measure PWV, cuffs were placed around the upper thigh and at the level of the 
carotid artery around the neck of the supine patient. The distance from the sternal notch to the top of the 
femoral cuff, in a straight line, was measured with a calibrated plastic tape measure, and PWV was calculated 
from this distance and the pulse transit time between the 2 points. The measurement was performed 3 times, 
and the average of the closest 2 measures was calculated. 
 
Statistical Analyses 
Due to the exploratory nature of this study, the statistical anal- ysis was limited to tests suitable for small 
samples (SPSS version 22.0: IBM). Descriptive statistics included the calculation of me- dian (interquartile 
range (IQR)) values over time for continuous outcome variables to measure trends. Changes in the 
distribution for continuous variables between baseline and 6 months were de- termined with Friedman’s 2-way 
analysis of variance by ranks; and the median (with 95% CIs) of the differences between the pre IGB and 6 
months post IGB values was calculated using the Hodges- Lehman median difference. Early balloon 
removals, complica- tions, adverse events, study withdrawals and reasons for withdraw- al were collected and 
analysed descriptively. 
 
 
Results 
Between April 2013 and October 2014, 72 patients sat- isfied the inclusion criteria and were contacted to par- 
ticipate in the study. Eleven consented to participate, while 1 withdrew from the study prior to IGB insertion. 
Ten patients had an IGB placed and there was 1 early re- moval after 3 days due to persistent vomiting; 9 
patients (3 male) completed the study. The median (IQR) age was 58 (49–68), with median eGFR being 23 
(17–40) ml/ min/1.73 m2, and median BMI being 40.2 (36.9–43.4) kg/ m2. The majority of patients belonged 
to the white ethnic group (8 White, 1 Black). Diabetes, with or without co- existing hypertension, was the 
major cause of CKD in 8 out of 11 patients; 2 patients developed CKD secondary to drug toxicity and 1 patient 
had lupus nephritis. All pa- tients were hypertensive and prescribed antihypertensive medication. Eight of the 9 
patients also had diabetes and all of them required anti-hyperglycaemic therapy. All pa- tients were well 
nourished at the time of entry into the study, as assessed by SGA, and they all remained well nourished 
throughout the study. 
Primary Efficacy Outcome 
The a priori efficacy criterion was at least a 10% re- duction in body mass 6 months after IGB insertion. The 
mean and median percentage weight loss after IGB insertion were 9.6% (SD 6.8%) and 9.1% (IQR 
13.6–%), respectively, after 6 months (fig. 1). Pre-IGB weight loss and the change in weight from this 
point to the baseline assessment pre-IGB placement is also included in figure 1. 
 
Safety – Complications and Adverse Events 
A summary of the complications and adverse events is presented in table 1. In 5 out of 10 (50%) patients, the ini- 
tial IGB insertion was abandoned due to gastritis. All patients with gastritis were treated with proton pump in- 
hibitors for 6 weeks and all had successful IGB insertion at the second attempt. The IGB early removal rate was 
9% (1/11 patients). There were 5 episodes of AKI post IGB insertion, occurring in 3 patients during the study 
(prevalence rate 30%). Two patients required hospitalization for severe vomiting, 1 received intravenous 
rehydration fluids and anti-emetics, and in the other, the IGB was re- moved 3 days post insertion. AKI 
occurred due to dehydration secondary to nausea and vomiting and/or ongoing use of diuretics. At the time of 
IGB removal, there was 1 case each of gastritis and esophagitis, diagnosed during endoscopy, neither of which 
was present at IGB insertion in these patients. There were no other adverse events di- rectly related to IGB 
placement in this study. 
 
Post study, after removal of the initial balloon, 4 pa- tients had a second balloon inserted and there were 2 cas- 
es of AKI secondary to dehydration in these patients, both requiring hospitalization for dehydration and intractable 
vomiting; they were treated with intravenous rehydration and anti-emetics. Overall, there was a 50% prevalence 
rate of AKI, with 5 of the 10 patients having at least 1 AKI event, and there were a total of 7 AKI events from 
14 IGB placements, including 2 severe adverse events during the study, defined as unexpected hospitalization 
related to a study procedure. 
Secondary Outcomes 
Serial measures and the median of the differences in between baseline and 6 months for the anthropometric, 
haemodynamic and metabolic outcomes are listed in ta- ble 2. After 6 months of IGB treatment, the Hodges 
Lehm- an median difference in body weight was –10.4 kg (95% CI –15.9 to –5.2; table 2). BMI, waist 
circumference, total cholesterol and leptin also decreased significantly after 6 months, and the reduction in 
low density lipoprotein cholesterol reached statistical significance (p = 0.059). BP, proteinuria, insulin resistance, 
arterial stiffness, markers of inflammation, other lipid fractions and adiponectin did not change in this cohort 
of obese patients with CKD, following treatment with IGB for 6 months. 
Discussion 
This study was the first to examine the safety and efficacy of IGB treatment for obesity in patients with mod- 
erate to advanced CKD. A priori efficacy of IGB treatment for obesity was almost reached with 9.6% weight 
loss, but there was a high rate of AKI following IGB insertion. The percentage of total body weight loss at 6 
months was less than the reported 12.2–13.6% weight loss in pooled meta-analyses of weight loss following 
IGB treat- ment in obese patients with normal kidney function [15, 16]. However, IGB treatment resulted in 
greater weight loss at 6 months compared to lifestyle treatment with a combination of dietary and physical 
activity changes with pharmacotherapy in obese patients with CKD [5]. The incidence of gastric lesions before 
IGB treatment IGB insertion. Gastritis is thought to be common in pa- tients with CKD, although there is a 
paucity of studies examining its incidence in patients with CKD not requir- ing renal replacement therapy. After 
IGB treatment, its incidence appears consistent with that reported in other studies in patients with normal 
kidney function. A 2007 Cochrane review of IGB treatment of reported a tenfold increased relative risk for 
gastric erosion compared to no IGB insertion [29], and 2 systematic reviews reported gastric erosion in 12–32% of 
patients post IGB treatment [15, 17]. This high rate of gastric erosion may also negatively impact the quality of 
life and medication burden, as treat- ment usually requires additional drug therapy. There was one case of early 
removal of the IGB due to poor toler- ance. A 2008 systematic review and meta-analysis reported an early 
removal rate of 4.2% [16]. Due to the small sample size, it is not possible to compare the rate of early balloon 
removal to that in other studies. 
 
Very few studies on IGB treatment report AKI as a complication, with reports of acute kidney failure, func- 
tional renal failure, or renal insufficiency at rates of 1.1– 4.5% of patients studied [18, 19, 30, 31]. In one 
study, acute renal failure was reported in 2 patients with diabetes being treated with metformin [19]. Factors 
associated with AKI include older age, proteinuria, hypertension, diabetes, and pre-existing CKD [32, 33]. The 
incidence of AKI in our study may have been higher than previously reported due to the increased risk of AKI 
associated with CKD, but also due to the close monitoring of kidney func- tion 1 and 2 weeks post IGB insertion, 
due to the antici- pated risk of AKI, secondary to volume depletion caused by nausea and vomiting. 
 
Interventions to reduce the risk of AKI, such as using sick day guidance [34] to temporarily cease ACE inhibi- tors 
and diuretics in patients with CKD at IGB insertion, until adequate fluid intake is established and post-proce- dure 
nausea and vomiting subsides, could potentially re- duce complications following IGB placement in patients with 
CKD. The benefit of this strategy needs careful con- sideration against the competing risks of possible uncon- 
trolled hypertension and hypervolemia with temporary cessation of these therapies. Additionally, prophylactic 
intravenous fluid therapy for several days may reduce the risk of dehydration; however, this is unlikely to be cost 
effective or practical if administering this therapy re- quires several days of hospitalization. 
 
Weight loss is associated with a reduction in inflam- matory cytokines, reduced insulin resistance and in- 
creased adiponectin [22, 23], but these relationships have not yet been well studied in obese patients with 
CKD. After IGB treatment, improvements in waist circumfer- ence, leptin and total cholesterol were evident, 
indicating a strong likelihood of a reduction in abdominal fat. Insu- lin resistance, CRP, and IL-6 all demonstrated 
a trend to- wards improvement in this study, also evident in previous studies of IGB in non-CKD participants [35–
38]. Due to the small sample size in this ‘first in CKD’ proof of con- cept safety study, trends in changes in 
metabolic factors may be useful for developing a hypothesis for the mecha- nisms associated with weight loss 
that may contribute to a reduction in CVD risk in this high-risk group of pa- tients. Arterial stiffness, measured 
by PWV, also demon- strated a trend towards improvement with weight loss in this study. PWV is a slow changing 
marker of arterial vas- culature health, and any beneficial effect may become more marked with longer term 
follow-up. A search of the literature did not identify any previous reports on the ef- fect of weight loss with IGB 
treatment on arterial stiffness in any population. Increased PWV, indicating increased large vessel arterial 
stiffness, is associated with obesity [39], and is an independent predictor of cardiovascular events in patients 
with stages 4–5 CKD, even after adjust- ment for established cardiovascular risk factors [40]. A reduction in 
arterial stiffness with a therapeutic interven- tion such as weight loss represents a true reduction in ar- terial wall 
damage, rather than simply a change in cardio- vascular risk scores [41]. These preliminary results indi- cate that 
weight loss in obese patients with CKD due to IGB treatment may contribute to reduced CVD risk, with the 
potential mechanism identified as a reduction in in- flammation leading to the modification of medial arterial 
wall structure. This hypothesis remains to be tested in future studies if improved safety can be demonstrated 
with a refined protocol including preventative measures to reduce the risk of AKI, as discussed. 
 
The major limitations of this study are the single-arm study design and small sample size. These limitations are 
true of most proof-of-concept studies, and the design mirrors that of phase 2 drug treatment studies to 
establish safety and efficacy in a small number of patients. The strength of this study was the close 
monitoring of kidney function post IGB insertion to examine safety. Using this design, we have detected a 
potentially high rate of AKI in a small number of patients, and we acknowledge that the study was not designed 
to detect metabolic and haemodynamic effects of weight loss in obese patients with CKD. 
 
The adverse event rate indicates that the IGB procedure, while moderately effective for weight loss, may carry a high 
rate of complications in obese patients with CKD. The risk of AKI may be raised due to a combination of increased 
dehydration secondary to gastrointestinal symptoms associated with IGB placement and reduced baseline kidney 
function. Studies including preventative measures to re- duce the risk of AKI, including cessation of ACE inhibitors 
and diuretics for a defined period, are recommended. 
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Table 1  
Nausea and vomiting in first week 8 of 10 patients 
 
AKI (5 episodes in 3 of 10 patients)  
Patient 5 1st AKI 1: 1 week post IGB insertion, vomiting daily, creatinine rose 
from 226 to 279 μmol/l, returned to baseline 1 week later; 
2nd AKI: 5 months post insertion, admitted with dehydration secondary to 
vomiting, AKI, (peak creatinine 650 μmol/l, potassium 3.3 mmol/l), 
diagnosis of viral gastroenteritis, IV fluids and anti-emetics given, 
creatinine fell to 310 μmol/l, 5 days later at discharge; 
3rd AKI: 6 months post insertion, readmitted with dehydration 
secondary to vomiting, AKI, hyponatremia (Na 114 mmol/l), diagnosis 
of esophageal candidiasis, IV fluids and anti-emetics given, IGB 
removed, creatinine 179 μmol/l, 1-week post discharge 
Patient 7 1-week post IGB insertion, creatinine rose from 460 to 538 μmol/l, nil 
vomiting reported, drinking 2 litres fluids/day, 2 weeks post IGB insertion 
creatinine 563 μmol/l, loperamide, furosemide and indapamide ceased, 
creatinine returned to baseline 4 weeks post IGB insertion 
 
Patient 9 1-month   post IGB insertion, creatinine rose from 280 μmol/l, 1 week post 
insertion to 474 μmol/l, furosemide and candesartan ceased, creatinine 
fell to 301 μmol/l, 1 week later 
Hospitalization for intravenous fluid therapy (2 of 10 patients) 
Patient 5 As detailed above 
Patient 10 Admitted 1-day post IGB insertion with intractable vomiting, creatinine 
rose from 
144 μmol/l at baseline to 173 μmol/l, 2 days post insertion, severe 
vomiting and nausea continued until IGB removed on day 3 post 
insertion 
Gastritis/esophagitis 2 of 9 patients 
 
Delayed IGB insertion 5 of 10 patients 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
            Complications/adverse events           Occurred, % 
  
 
Table 2  Anthropometric, haemodynamic and metabolic parameters (median and IQR) pre and post IGB 
placement in obese patients with CKD 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
Figure 1.  Body weight changes with diet and exercise only and after IGB insertion in obese 
patients with CKD (dashed lines – individual patient data, heavy line – median body weight 
change). 
 
 
 
 
 
 
 
